A Double-Blind, Placebo-Controlled, Randomized, Single Ascending Dose Study to Investigate Safety, Tolerability, and Pharmacokinetics of ALS-008176 in Healthy Japanese Adult Subjects
Phase of Trial: Phase I
Latest Information Update: 27 Jul 2015
At a glance
- Drugs Lumicitabine (Primary)
- Indications Respiratory syncytial virus infections
- Focus Pharmacokinetics
- Sponsors Janssen Pharmaceutical KK
- 23 Jul 2015 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 06 Jul 2015 Status changed from recruiting to active, no longer recruiting, according to ClinicalTrials.gov record.
- 25 Jun 2015 New trial record